Member Info for Toukankahmoon

Thorn

Point taken.

Also another reason why long term(and we are all LTHs on here aren’t we) we don’t want Avacta taken over by BP only to become a cash cow for their other developments.

HarChris

It is easy to infer from Grok’s excellent analysis that I have few holdings. In fact I have shares in more than a couple of dozen companies across half a dozen accounts. But I only read bulletin boards for my “penny shares” largely because they are overly impacted by sentiment rather than traditional core values. And I only post on those boards when I see some ludicrous pronouncement with no factual basis other than the poster wishes it were so!!!!

For 80% of my investment portfolio, I use traditional analysis methods and broker forecasts etc

Pedrol fair enough. Guilty as charged. Have a great day😁

Good thread

Opti : I think that is what we have been led to expect but I have been disappointed before so not holding my breath.

Craig. : it’s been in the wings for sooo long🤞🤞🤞

Thanks for posting

HarChris

I haven’t deleted the post.

And I am genuinely humbled for that piece of self awareness. A lot of my posts that contain 20p are a rebuff to others like BV who keep reminding me of something I posted nearly a year ago.

Anyway “They aren't a pure deramper (they appear to hold a decent position and celebrate good news when it arrives), but they are relentlessly focused on the downside risks, and the 20p/lowball placing scenario is absolutely something they have pushed repeatedly.”

Sounds reasonable.

I don’t use Grok. For balance why don’t you ask it about Timster and his twat. Or Watching and some of their recurring themes. And there are others. I bet Grok will have far worse things to say about them.

But you won’t will you because you are in the same tribe.

GLA

Is that breaching FCA board guidelines 🤣🤣🤣🤣🤣🤣

Southstreet

Overall I agree with your sentiments. I cannot see a decent TO short term and would far prefer licensing deals.

As to the real long term, pharmaceuticals rarely pay a decent dividend (R&D costs to continue their pipelines are too high). So I’d say sell in a couple of years and put the money into something that will give you 10%+ dividend

As to CJ, they’re a trader after all

If only. Bring it on. Will stop all the stupid predictions of “Takeover next week” etc

Thorn

You don’t understand. You aren’t allowed to reassess your investment even when the outlook has fundamentally changed. You have to continue to be pessimistic. This BB isn’t about rationally discussing Avacta’s potential, it’s about joining a tribe and throwing as much scorn and abuse at those who aren’t in the tribe as you possibly can. 🤣🤣🤣

Reaper

There are many “types” of AI. Most people are making the mistake that ChatGPT is the total be all and end all of AI. Useful as ChatGPT is, this is a disservice to the other AI technologies and uses.

A not very important example of AI is in my Samsung 8k TV that uses 256 neural networks to upscale the TV images. Just one example of many more types of AI.

BV

Thanks for that. Seems like a poor approach compared with Avacta. Though rather a head in sand stance by Astrazenica.

In other news, I will be taking part in the inaugural Imperial College AI forum this week. After updating my knowledge, perhaps I will be able to discuss it with Wyndrum 😁😁😁😁

BV

So is Astrazenica’s focus on FAP inhibitors?

Thanks for posting

I guess Astrazenica won’t be bidding for us if they can develop their own FAP targeted drugs.

Go HEMO go!!!

Haven’t you lot got Christmas lunches and more enjoyable things to do than continually torturing eachother with stupid unfounded predictions???

BenH

As posted earlier with my investment guru hat on. Oh no sorry, I just looked at the calendar.

ITS A LONG BANK HOLIDAY NOW IN USA SO HIGHLY UNLIKELY THERE WILL BE AN RNS

Regarding your mate Apre: I find it hilarious that they get so wound up after disastrously ramping ABDX at around 9p about two years ago.

Use some of those ABDX profits. Oh hold on you haven’t made any 🤣

IceCool

“Pivotal doesn’t mean the science isn’t clear it means the regulators want a bigger sample. The science is already nailed.”

You arrogant prick.

In reality the science isn’t nailed until the FDA says it is regardless of what our resident experts say.

Anyway that wasn’t my point as you well know. Even CC understands the importance of publishing excellent P1b results.

And as I have said, I do still believe that the risk reward balance still favours being invested. Accordingly I shall disappoint you by stating that I am well inviting Avacta.

None of the above.

DYOR